Researchers at University of Arizona and University of Dundee have disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes, osteoarthritis, Down syndrome, inflammatory disorder, autoimmune and Alzheimer’s disease.
PDC*line Pharma SA has announced the selection of the PDC*neo+ project for funding by the Walloon region of Belgium and Biowin, the health cluster for Wallonia.
DNA replication stress induced by oncogenes is a known driver of chromosomal instability, which is associated with poor prognosis in several cancer types.
The combination of chemotherapy (CT) and photodynamic therapy (PDT), which combines light and a photosensitizing agents, is increasingly being used to enhance the efficacy of cancer treatments.
Angiopoietin-like 4 (ANGPTL4) is a glycosylated and secreted protein that functions as a regulator of cell metabolism and angiogenesis, and which has been shown to play a critical role in tumorigenesis.
Researchers from China have elucidated the prognostic role of aberrant expression of RNA binding motif protein, X chromosome (RBMX) in several cancer types using samples from cancer patients.
PDC*line Pharma SA has received €4.7 million (US$5.1 million) in public funding as part of a €12.5 million project to apply its allogeneic leukemia-derived dendritic cell line in the development of personalized vaccines for treating colorectal cancer.
Dermasensor Inc. received U.S. FDA clearance for its non-invasive skin cancer evaluation device that provides quantitative identification of all skin cancer types at the point of care and within seconds. The point-and-click device is designed to facilitate detection of skin cancers by primary care physicians (PCPs) and speed the time to diagnosis and treatment.
The Cleveland Clinic Foundation has described 3-β-hydroxysteroid dehydrogenase/δ5-->4-isomerase type 1 (3β-HSD I) inhibitors reported to be useful for the treatment of cancer.
RSS
